AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2817305 — intervention group
Group type: EXPERIMENTAL
Intervention: Dp-treated group (unmodified Dp extract)
Number of subjects: 46
Study 2817305 — intervention group
Group type: EXPERIMENTAL
Intervention: mPEG-Dp group (mPEG modified Dp extract)
Number of subjects: 46
Study 2817305 — intervention group
Group type: COMPARATOR
Intervention: Control group (no injections)
Number of subjects: 46
Study 2817305 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (after 2 years)
Number of subjects: 46
Study 2817305 — intervention group
Group type: EXPERIMENTAL
Intervention: Retrospective questionnaire data
Number of subjects: 46
Study 1234486 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (300 mg)
Number of subjects: 3
Study 1234486 — intervention group
Group type: EXPERIMENTAL
Intervention: Practolol (400 mg)
Number of subjects: 3
Study 1234486 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 mg)
Number of subjects: 3
Study 30859680 — intervention group
Group type: COMPARATOR
Intervention: Standard omeprazole doses
Number of subjects: 133
Study 30859680 — intervention group
Group type: EXPERIMENTAL
Intervention: Personalized therapy based on CYP2C19 polymorphism
Number of subjects: 133
Study 28371078 — intervention group
Group type: EXPERIMENTAL
Intervention: 10% D/DC-containing cream
Number of subjects: 50
Study 28371078 — intervention group
Group type: EXPERIMENTAL
Intervention: 20% D/DC-containing cream
Number of subjects: 50
Study 28371078 — intervention group
Group type: COMPARATOR
Intervention: White petrolatum
Number of subjects: 50
Study 28371078 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 50
Study 28371078 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Analog Scale (VAS) scores for pruritus in D/DC-treated groups
Number of subjects: 50
Study 26460279 — intervention group
Group type: EXPERIMENTAL
Intervention: Prasugrel (loading/maintenance dose: 20/3.75 mg)
Number of subjects: 1363
Study 26460279 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (loading/maintenance dose: 300/75 mg)
Number of subjects: 1363
Study 23181738 — intervention group
Group type: EXPERIMENTAL
Intervention: Ingesting all prescribed once-a-day hypertension medications upon awakening
Number of subjects: 2156
Study 23181738 — intervention group
Group type: COMPARATOR
Intervention: Ingesting ≥1 medications at bedtime
Number of subjects: 2156
Study 23181738 — intervention group
Group type: COMPARATOR
Intervention: Asleep systolic BP mean <103 mm Hg
Number of subjects: 2156
Study 23181738 — intervention group
Group type: COMPARATOR
Intervention: Bedtime hypertension treatment
Number of subjects: 2156
Study 23181738 — intervention group
Group type: COMPARATOR
Intervention: Progressive reduction in asleep BP mean
Number of subjects: 2156
Study 21823378 — intervention group
Group type: EXPERIMENTAL
Intervention: SLIPA
Number of subjects: 58
Study 21823378 — intervention group
Group type: COMPARATOR
Intervention: LMA
Number of subjects: 58
Study 21823378 — intervention group
Group type: COMPARATOR
Intervention: Comparison of SLIPA and LMA
Number of subjects: 58
Study 17917685 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate Sequential Cataract Surgery (ISCS)
Number of subjects: 220
Study 17917685 — intervention group
Group type: COMPARATOR
Intervention: Delayed Sequential Cataract Surgery (DSCS)
Number of subjects: 220
Study 16754269 — intervention group
Group type: EXPERIMENTAL
Intervention: Candesartan 8‐16 mg daily
Number of subjects: 4937
Study 16754269 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4937
Study 15816267 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbohydrate test foods (bread, roti, rice) consumed by Type 2 diabetic patients
Number of subjects: 38
Study 15816267 — intervention group
Group type: COMPARATOR
Intervention: Healthy non-diabetic subjects
Number of subjects: 38
Study 15816267 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetic patients visiting either clinic
Number of subjects: 38
Study 11571822 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (impulse magnetic-field therapy, 16 Hz, 5 microTs)
Number of subjects: 82
Study 11571822 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 82
Study 9784038 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral Imedeen
Number of subjects: 144
Study 9784038 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 144
Study 8152361 — intervention group
Group type: EXPERIMENTAL
Intervention: Methods of rank order, category scaling, time tradeoff, and standard gamble
Number of subjects: 0
Study 8152361 — intervention group
Group type: COMPARATOR
Intervention: Nursing home residents
Number of subjects: 0
Study 8152361 — intervention group
Group type: EXPERIMENTAL
Intervention: Current health and severe constant pain
Number of subjects: 0
Study 8152361 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia and coma
Number of subjects: 0
Study 2578012 — intervention group
Group type: COMPARATOR
Intervention: Mantle irradiation (M)
Number of subjects: 494
Study 2578012 — intervention group
Group type: COMPARATOR
Intervention: Extended field mantle plus para‐aortic (M + PA) irradiation
Number of subjects: 494
Study 2578012 — intervention group
Group type: EXPERIMENTAL
Intervention: Sandwiched mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) X 3, M irradiation, MOPP X 3 protocol (3M)
Number of subjects: 494
Study 2578012 — intervention group
Group type: COMPARATOR
Intervention: Total/subtotal nodal irradiation (TNI/STNI)
Number of subjects: 494
Study 2578012 — intervention group
Group type: EXPERIMENTAL
Intervention: 3M
Number of subjects: 494
Study 2578012 — intervention group
Group type: COMPARATOR
Intervention: TNI/STNI
Number of subjects: 494
Study 28719008 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemigliptin (50 mg)
Number of subjects: 132
Study 28719008 — intervention group
Group type: COMPARATOR
Intervention: Placebo transitioned to Linagliptin
Number of subjects: 132
Study 28719008 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemigliptin
Number of subjects: 132
Study 28719008 — intervention group
Group type: COMPARATOR
Intervention: Linagliptin
Number of subjects: 132
Study 27894327 — intervention group
Group type: EXPERIMENTAL
Intervention: Targeted temperature management (TTM) at 33 (±1) °C for 48 hours
Number of subjects: 355
Study 27894327 — intervention group
Group type: COMPARATOR
Intervention: Targeted temperature management (TTM) at 33 (±1) °C for 24 hours
Number of subjects: 355
Study 24438386 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching routine (DS1; 6.7 ± 1.3 min)
Number of subjects: 26
Study 24438386 — intervention group
Group type: EXPERIMENTAL
Intervention: Dynamic stretching routine (DS2; 12.1 ± 1.6 min)
Number of subjects: 26
Study 24438386 — intervention group
Group type: COMPARATOR
Intervention: Control condition (CON; 5‐min jog + 12 min of resting)
Number of subjects: 26
Study 22943969 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated patch (4 lidocaine/tetracaine patches, 70/70 mg) for 2 hours
Number of subjects: 12
Study 22943969 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated patch (4 lidocaine/tetracaine patches, 70/70 mg) for 4 hours
Number of subjects: 12
Study 22943969 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated patch (4 lidocaine/tetracaine patches, 70/70 mg) for 12 hours
Number of subjects: 12
Study 22943969 — intervention group
Group type: COMPARATOR
Intervention: Unheated patch (4 lidocaine/tetracaine patches, 70/70 mg) for 4 hours
Number of subjects: 12
Study 22943969 — intervention group
Group type: EXPERIMENTAL
Intervention: Heated patch (4 lidocaine/tetracaine patches, 70/70 mg)
Number of subjects: 12
Study 21095263 — intervention group
Group type: EXPERIMENTAL
Intervention: Ezetimibe 10 mg plus Simvastatin 20 mg daily
Number of subjects: 9438
Study 21095263 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg daily
Number of subjects: 9438
Study 21095263 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9438
Study 18692886 — intervention group
Group type: EXPERIMENTAL
Intervention: Levalbuterol HFA MDI (45 microg per dose)
Number of subjects: 49
Study 18692886 — intervention group
Group type: COMPARATOR
Intervention: Racemic albuterol HFA MDI (90 microg per dose)
Number of subjects: 49
Study 15960560 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (40-120 mg/day)
Number of subjects: 1466
Study 15960560 — intervention group
Group type: EXPERIMENTAL
Intervention: Paroxetine (20 mg/day)
Number of subjects: 1466
Study 15960560 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1466
Study 15960560 — intervention group
Group type: EXPERIMENTAL
Intervention: Duloxetine (80-120 mg/day)
Number of subjects: 1466
Study 12610044 — intervention group
Group type: EXPERIMENTAL
Intervention: Pioglitazone (45 mg o.d. for >26 weeks)
Number of subjects: 131
Study 10515398 — intervention group
Group type: COMPARATOR
Intervention: Continuous training (C)
Number of subjects: 21
Study 10515398 — intervention group
Group type: EXPERIMENTAL
Intervention: Interval training (I)
Number of subjects: 21
Study 10515398 — intervention group
Group type: EXPERIMENTAL
Intervention: Both training groups (C and I)
Number of subjects: 21
Study 7669958 — intervention group
Group type: EXPERIMENTAL
Intervention: Low loading dose of milrinone (20 micrograms/kg during 15 minutes)
Number of subjects: 20
Study 7669958 — intervention group
Group type: COMPARATOR
Intervention: High loading dose of milrinone (40 micrograms/kg during 15 minutes)
Number of subjects: 20
Study 2256645 — intervention group
Group type: EXPERIMENTAL
Intervention: Imocur
Number of subjects: 64
Study 2256645 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 6770673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (40 mg/kg/day for 10 days to 3 weeks)
Number of subjects: 218
Study 6770673 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin trihydrate (40 mg/kg/day for 10 days to 3 weeks)
Number of subjects: 218
Study 6770673 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefaclor (20 mg/kg/day for 10 days)
Number of subjects: 218
Study 6770673 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V potassium (20 mg/kg/day for 10 days)
Number of subjects: 218
Study 31018684 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise plus usual care (n = 21)
Number of subjects: 41
Study 28240983 — intervention group
Group type: EXPERIMENTAL
Intervention: Digits-in-noise (DIN) test administered via personal computer
Number of subjects: 40
Study 28240983 — intervention group
Group type: EXPERIMENTAL
Intervention: Hearing Handicap Inventory for Adults (HHIA) questionnaire
Number of subjects: 40
Study 28391665 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening dentifrice with sodium fluoride and sodium hexametaphosphate (SHMP)
Number of subjects: 50
Study 28391665 — intervention group
Group type: COMPARATOR
Intervention: Dental prophylaxis
Number of subjects: 50
Study 24616337 — intervention group
Group type: EXPERIMENTAL
Intervention: EUROACTION PLUS (EA+)
Number of subjects: 696
Study 24616337 — intervention group
Group type: COMPARATOR
Intervention: Usual Care (UC)
Number of subjects: 696
Study 23094264 — intervention group
Group type: EXPERIMENTAL
Intervention: Electric toothbrush (Colgate Motion)
Number of subjects: 40
Study 23094264 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrush (Oral‐B Advantage)
Number of subjects: 40
Study 23094264 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrush (Oral‐B CrossAction)
Number of subjects: 40
Study 23094264 — intervention group
Group type: EXPERIMENTAL
Intervention: Manual toothbrush (Oral‐B ShinyClean)
Number of subjects: 40
Study 19823185 — intervention group
Group type: EXPERIMENTAL
Intervention: 1500 mg dairy and non-dairy calcium
Number of subjects: 34
Study 19823185 — intervention group
Group type: COMPARATOR
Intervention: 500 mg dairy and non-dairy calcium
Number of subjects: 34
Study 18171957 — intervention group
Group type: COMPARATOR
Intervention: Eccentric loading (Group 1)
Number of subjects: 50
Study 18171957 — intervention group
Group type: EXPERIMENTAL
Intervention: Shock wave therapy (Group 2)
Number of subjects: 50
Study 16120776 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo with expected analgesic properties
Number of subjects: 0
Study 12590855 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin (400 mg, 7-day regimen)
Number of subjects: 452
Study 12590855 — intervention group
Group type: COMPARATOR
Intervention: Trovafloxacin (200 mg, 10-day regimen)
Number of subjects: 452
Study 10232720 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 100 microg x kg(‐1)
Number of subjects: 90
Study 10232720 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study 8934467 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D‐CTA
Number of subjects: 52
Study 8934467 — intervention group
Group type: EXPERIMENTAL
Intervention: CEA
Number of subjects: 52
Study 8934467 — intervention group
Group type: EXPERIMENTAL
Intervention: STA‐MCA anastomosis
Number of subjects: 52
Study 8452170 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin 400 mg once daily for 7 days
Number of subjects: 625
Study 8452170 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin 500 mg every 8 hours for 7 days
Number of subjects: 625
Study 8452170 — intervention group
Group type: EXPERIMENTAL
Intervention: Fleroxacin
Number of subjects: 625
Study 8452170 — intervention group
Group type: COMPARATOR
Intervention: Amoxicillin
Number of subjects: 625
Study 3540918 — intervention group
Group type: EXPERIMENTAL
Intervention: Tripotassium dicitrato bismuthate (TDB) administered twice daily
Number of subjects: 53
Study 3540918 — intervention group
Group type: COMPARATOR
Intervention: Tripotassium dicitrato bismuthate (TDB) administered four times daily
Number of subjects: 53
Study 29917255 — intervention group
Group type: EXPERIMENTAL
Intervention: Avatar-based heart attack education application
Number of subjects: 70
Study 29917255 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 70
Study 27693654 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobacco Heating System 2.2 (THS 2.2)
Number of subjects: 160
Study 27693654 — intervention group
Group type: COMPARATOR
Intervention: Conventional Cigarettes (CCs)
Number of subjects: 160
Study 27693654 — intervention group
Group type: COMPARATOR
Intervention: Smoking Abstinence
Number of subjects: 160
Study 23749481 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong exercise (18 Forms Tai Chi Internal Qigong for approximately 6 minutes)
Number of subjects: 23
Study 23749481 — intervention group
Group type: COMPARATOR
Intervention: Control group (resting for similar duration in a sitting position)
Number of subjects: 23
Study 23749481 — intervention group
Group type: EXPERIMENTAL
Intervention: Qigong exercise
Number of subjects: 23
Study 25092441 — intervention group
Group type: EXPERIMENTAL
Intervention: Mirabegron 50 mg once-daily
Number of subjects: 0
Study 25092441 — intervention group
Group type: COMPARATOR
Intervention: Tolterodine ER 4 mg
Number of subjects: 0
Study 25092441 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 22024905 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose supervised strengthening exercise with spinal manipulation (ET + SMT)
Number of subjects: 270
Study 22024905 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose supervised strengthening exercise (ET)
Number of subjects: 270
Study 19606689 — intervention group
Group type: EXPERIMENTAL
Intervention: Johrei treatment (18 sessions over 6 weeks)
Number of subjects: 39
Study 19606689 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control
Number of subjects: 39
Study 17595258 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant GH (50 mug/kg.d; n = 45)
Number of subjects: 88
Study 17595258 — intervention group
Group type: COMPARATOR
Intervention: No treatment (n = 43)
Number of subjects: 88
Study 17595258 — intervention group
Group type: COMPARATOR
Intervention: Between-group comparison
Number of subjects: 88
Study 15720887 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of nevirapine (NVP)
Number of subjects: 1755
Study 15720887 — intervention group
Group type: COMPARATOR
Intervention: NVP with zidovudine (ZDV) twice daily for a week
Number of subjects: 1755
Study 15720887 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral prophylaxis
Number of subjects: 1755
Study 15720887 — intervention group
Group type: EXPERIMENTAL
Intervention: Short regimens of antiretrovirals
Number of subjects: 1755
Study 15720887 — intervention group
Group type: COMPARATOR
Intervention: HIV infection
Number of subjects: 1755
Study 15720887 — intervention group
Group type: EXPERIMENTAL
Intervention: Granulocytopenia observed
Number of subjects: 1755
Study 11812553 — intervention group
Group type: EXPERIMENTAL
Intervention: Community physiotherapy
Number of subjects: 170
Study 11812553 — intervention group
Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 170
Study 9808797 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutrition intervention activities
Number of subjects: 107
Study 9808797 — intervention group
Group type: COMPARATOR
Intervention: Control sites
Number of subjects: 107
Study 9808797 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention worksites
Number of subjects: 107
Study 8758248 — intervention group
Group type: EXPERIMENTAL
Intervention: Clodronate
Number of subjects: 244
Study 8758248 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 244
Study 1917265 — intervention group
Group type: EXPERIMENTAL
Intervention: Newsletters
Number of subjects: 45
Study 1917265 — intervention group
Group type: EXPERIMENTAL
Intervention: Newsletters reinforced by a group seminar
Number of subjects: 45
Study 1917265 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 45
Study 6214377 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical erythromycin 1.5 percent solution (Staticin solution)
Number of subjects: 54
Study 6214377 — intervention group
Group type: COMPARATOR
Intervention: Oral tetracycline (250 mg twice a day)
Number of subjects: 54
Study 31488063 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiretroviral therapy (ART) adherence
Number of subjects: 270
Study 31488063 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended 3-month ART supply
Number of subjects: 270
Study 31488063 — intervention group
Group type: EXPERIMENTAL
Intervention: Viral load measurements
Number of subjects: 270
Study 31488063 — intervention group
Group type: EXPERIMENTAL
Intervention: Time since ART initiation, female gender, primary breadwinner status
Number of subjects: 270
Study 31488063 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment failure
Number of subjects: 270
Study 31488063 — intervention group
Group type: COMPARATOR
Intervention: Concurrent ART and tuberculosis treatment
Number of subjects: 270
Study 31488063 — intervention group
Group type: COMPARATOR
Intervention: Switching to a second line ART regimen with higher pill burden
Number of subjects: 270
Study 28369381 — intervention group
Group type: EXPERIMENTAL
Intervention: Maraviroc 300 mg twice daily
Number of subjects: 213
Study 28369381 — intervention group
Group type: COMPARATOR
Intervention: Kaletra® 400/100 mg plus tenofovir disoproxil/emtricitabine (200/245 mg) once daily
Number of subjects: 213
Study 28369381 — intervention group
Group type: COMPARATOR
Intervention: Kaletra® arm
Number of subjects: 213
Study 28369381 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 213
Study 26869244 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-GI SSB (isomaltulose)
Number of subjects: 13
Study 26869244 — intervention group
Group type: COMPARATOR
Intervention: High-GI SSB (75% maltodextrin + 25% sucrose)
Number of subjects: 13
Study 24931956 — intervention group
Group type: EXPERIMENTAL
Intervention: NEMEX-TJR (neuromuscular exercise intervention)
Number of subjects: 165
Study 22391336 — intervention group
Group type: EXPERIMENTAL
Intervention: Valerian acupressure
Number of subjects: 85
Study 22391336 — intervention group
Group type: COMPARATOR
Intervention: Regular treatment (Control)
Number of subjects: 85
Study 18495403 — intervention group
Group type: EXPERIMENTAL
Intervention: PMCT
Number of subjects: 80
Study 18495403 — intervention group
Group type: EXPERIMENTAL
Intervention: PEI followed by PMCT
Number of subjects: 80
Study 18495403 — intervention group
Group type: EXPERIMENTAL
Intervention: PEI followed by PMCT with occlusion of the feeding artery
Number of subjects: 80
Study 17634169 — intervention group
Group type: EXPERIMENTAL
Intervention: Pinto beans
Number of subjects: 16
Study 17634169 — intervention group
Group type: EXPERIMENTAL
Intervention: Black-eyed peas
Number of subjects: 16
Study 17634169 — intervention group
Group type: COMPARATOR
Intervention: Placebo (carrots)
Number of subjects: 16
Study 14981523 — intervention group
Group type: EXPERIMENTAL
Intervention: Fragile X syndrome (FXS)
Number of subjects: 0
Study 14981523 — intervention group
Group type: EXPERIMENTAL
Intervention: Fmr1-knockout mice
Number of subjects: 0
Study 11452635 — intervention group
Group type: EXPERIMENTAL
Intervention: Biphasic pulses (4 ms duration per phase, balanced 3:1 ratio of first to second phase peak voltages)
Number of subjects: 2
Study 11452635 — intervention group
Group type: COMPARATOR
Intervention: Monophasic damped sinusoid waveform
Number of subjects: 2
Study 11452635 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of transmembrane voltage decay time ratios
Number of subjects: 2
Study 9836063 — intervention group
Group type: EXPERIMENTAL
Intervention: High-danger instruction condition
Number of subjects: 18
Study 9836063 — intervention group
Group type: COMPARATOR
Intervention: Low-danger instruction condition
Number of subjects: 18
Study 8009740 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute transverse colostomy, suture and omental covering of a visible perforation
Number of subjects: 62
Study 8009740 — intervention group
Group type: COMPARATOR
Intervention: Acute resection without primary anastomosis
Number of subjects: 62
Study 8009740 — intervention group
Group type: COMPARATOR
Intervention: Hartmann's procedure
Number of subjects: 62
Study 8009740 — intervention group
Group type: COMPARATOR
Intervention: Exteriorization of both lumens
Number of subjects: 62
Study 8009740 — intervention group
Group type: COMPARATOR
Intervention: Colostomy
Number of subjects: 62
Study 8009740 — intervention group
Group type: COMPARATOR
Intervention: Acute resection
Number of subjects: 62
Study 8009740 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute colostomy
Number of subjects: 62
Study 1724233 — intervention group
Group type: EXPERIMENTAL
Intervention: Disopyramide alone
Number of subjects: 29
Study 1724233 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine alone
Number of subjects: 29